Product Information
VENLAFAXINE HCL ER 225 MG TAB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.4712 per EA under NDC 31722012690. Its NADAC has been published 286 times since Apr 14, 2021.
FDA first approved this application on Oct 21, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
225 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722012690
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214419FDA Approved
10/21/2020
TE Code
AB
On Market Since
10/23/2020
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 225 MG TAB has been published 286 times since Apr 14, 2021, and over the history we have for it it has declined 87.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4712 per EA |
|---|---|
| All-time high | $4.2991 (Jul 14, 2021) |
| All-time low | $0.4592 (Nov 20, 2024) |
| 52-week high | $0.6436 |
| 52-week low | $0.4614 |
| Median price | $0.7786 |
| Average price | $1.4909 |
| Largest weekly change | +54.1% (Feb 22, 2023) |
| Weeks tracked | 286 |
| Tracking since | Apr 14, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
venlafaxine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 225 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 225 MG TAB, manufactured by Camber Pharmaceuticals Inc., is $0.4712 per EA (NDC 31722012690), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 225 MG TAB changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 225 MG TAB has declined 87.9%. It has been tracked across 286 weekly CMS publications since Apr 14, 2021.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 225 MG TAB?
Since Apr 14, 2021, the NADAC for VENLAFAXINE HCL ER 225 MG TAB has ranged from a low of $0.4592 (Nov 20, 2024) to a high of $4.2991 (Jul 14, 2021), with a median of $0.7786 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 225 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VENLAFAXINE HCL ER 225 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures VENLAFAXINE HCL ER 225 MG TAB?
VENLAFAXINE HCL ER 225 MG TAB (NDC 31722012690) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.